SILENCE THER. (SLN)
SLN Share PerformanceMore
|52 week high||169.75 18/12/15|
|52 week low||96.65 10/08/16|
|52 week change||-56.25 (-34.09%)|
|4 week volume||301,569 11/11/16|
Latest News« previous» nextMore
15/11/2016 - 07:00 RNS
RNS Number: 1506P Silence Therapeutics PLC 15 November 2016 CRISPR/Cas9 Gene Editing Data A single-particle RNA based approach to in vivo CRISPR/Cas9 gene editing London, 15 November 2016 - Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment o...
27/09/2016 - 13:50 StockMarketWire
Canaccord Genuity today reaffirms its buy investment rating on Silence Therapeutics PLC (LON:SLN) and raised its price...
27/09/2016 - 08:53 StockMarketWire
Silence Therapeutics has turned in an H1 pretax loss of 5.5m, from a year-earlier's loss of 4.1m. "Silence has been fully focus...
27/09/2016 - 06:00 RNS
RNS Number: 8769K Silence Therapeutics PLC 27 September 2016 27 Sept e mber 2 0 16 I n t e r i m results for the six months ended 30 June 2016 Liver focus, patent portfolio validation and strengthened leadership L o n d o n , 27 S e p t emb e r 2 0 1 6 - Sil e n ce Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery and developm...
22/09/2016 - 06:00 RNS
RNS Number: 4927K Silence Therapeutics PLC 22 September 2016 22 September 2016 Notice of Results London, 22 September 2016 - Silence Therapeutics plc, AIM:SLN ("Silence" or the "the Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, will announce results f...
05/09/2016 - 06:00 RNS
RNS Number: 8797I Silence Therapeutics PLC 05 September 2016 5 September 2016 Silence Therapeutics appoints Dmitry Samarsky, PhD as Chief Scientific Officer and Dr Andy Richards CBE as Non-Executive Director Silence Therapeutics Plc, AIM: SLN, (" Silence " or " the Company ") a leader in the discovery, delivery and development of novel RNA therapeutic...
18/07/2016 - 06:00 RNS
RNS Number: 3962E Silence Therapeutics PLC 18 July 2016 Grant of share options to Chief Financial Officer 18 July 2016 Pursuant to the announcement of 24 May 2016, Silence Therapeutics plc ("Silence" or the "Company"), AIM: SLN, a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, confirms that D...
17/06/2016 - 14:54 StockMarketWire
Silence Therapeutics, a leader in the development and delivery of novel RNA therapeutics, has confirmed that all resolutio...
|Dividend yield||0 %|
Latest discussion posts More
“o/t Thanks to all those that have supported this campaign ~~~~~ *3,717 voted so far~~~~~(That's a lot of irate investors?) Campaign to make short-selling illegal (or ...”▼
“'I am pleased by the support of key investors at a time of heavy market volatility. I look forward to progressing Silence's pipeline with our expanded resources.' and all ...”▼
Codes & Symbols
|Symbols||SLN, LSE:SLN, SLN.L, SLN:LN, LON:SLN, XLON:SLN|